An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells

Michihiko Wada, Ryo Hosotani, Jeon Uk Lee, Ryuichiro Doi, Takatomo Koshiba, Koji Fujimoto, Yoshiharu Miyamoto, Shoichiro Tsuji, Sanae Nakajima, Akira Okuyama, Masayuki Imamura

研究成果: Article

23 引用 (Scopus)

抜粋

We investigated the effects of an exogenous cdk inhibitor, butyrolactone-I, on cell growth inhibition, apoptosis induction, and the regulation of apoptosis in pancreatic cancer cells with mutated p53. Cell growth was dose-dependently inhibited by Butyrolactone-I in PANC-1 and AsPC-1 cells. Phosphorylation of pRb and Cyclin A expression were significantly inhibited in Butyrolactone-I-treated cells. Apoptotic cell death was detected by both Hoechst staining and TUNEL assay. In butyrolactone-I-treated PANC-1 cells, expression of p53 protein was unchanged, but Bax expression was slightly up-regulated and Bcl-2 expression was predominantly down-regulated. Bax/Bcl-2 ratio reached 9.6-fold increase compared to the control at the maximum. The time course of changes in Bax/Bcl-2 ratio was similar to that in the TUNEL-positive ratio. These data, suggest that dynamic changes of the Bax/Bcl-2 ratio might be important in determining point of apoptosis induction in pancreatic cancer cells with p53 mutation.

元の言語English
ページ(範囲)2559-2566
ページ数8
ジャーナルAnticancer research
18
発行部数4 A
出版物ステータスPublished - 01-07-1998

    フィンガープリント

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Wada, M., Hosotani, R., Lee, J. U., Doi, R., Koshiba, T., Fujimoto, K., Miyamoto, Y., Tsuji, S., Nakajima, S., Okuyama, A., & Imamura, M. (1998). An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells. Anticancer research, 18(4 A), 2559-2566.